Efficacy and safety of a vaginal medicinal product containing three strains of probiotic bacteria: a multicenter, randomized, double-blind, and placebo-controlled trial
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The main objective of this study was to evaluate whether vaginal administration of probiotic Lactobacillus results in their colonization and persistence in the vagina and whether Lactobacillus colonization promotes normalization and maintenance of pH and Nugent score. PATIENTS AND METHODS: The study was a multicenter, randomized, double-blind, and placebo-controlled trial. Altogether, 376 women were assessed for eligibility, and signed informed consent. One hundred and sixty eligible women with abnormal, also called intermediate, vaginal microflora, as indicated by a Nugent score of 4-6 and pH >4.5 and zero or low Lactobacillus count, were randomized. Each participant was examined four times during the study. Women were randomly allocated to receive either the probiotic preparation inVag(®), or a placebo (one capsule for seven consecutive days vaginally). The product inVag includes the probiotic strains Lactobacillus fermentum 57A, Lactobacillus plantarum 57B, and Lactobacillus gasseri 57C. We took vaginal swabs during visits I, III, and IV to determine the presence and abundance of bacteria from the Lactobacillus genus, measure the pH, and estimate the Nugent score. Drug safety evaluation was based on analysis of the types and occurrence of adverse events. RESULTS: Administration of inVag contributed to a significant decrease (between visits) in both vaginal pH (P<0.05) and Nugent score (P<0.05), and a significant increase in the abundance of Lactobacillus between visit I and visits III and IV (P<0.05). Molecular typing revealed the presence of Lactobacillus strains originating from inVag in 82% of women taking the drug at visit III, and 47.5% at visit IV. There was no serious adverse event related to inVag administration during the study. CONCLUSION: The probiotic inVag is safe for administration to sustainably restore the healthy vaginal microbiota, as demonstrated by predominance of the Lactobacillus bacteria in vaginal microbiota.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Besselink, M. G., van Santvoort, H. C., Buskens, E., Boermeester, M. A., van Goor, H., Timmerman, H. M., Nieuwenhuijs, V. B., Bollen, T. L., van Ramshorst, B., Witteman, B. J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60207-x · Cited by 1,367 · cited 1×
“These adverse events may include allergic reactions related to a hypersensitivity to components in the probiotic.(16,17) Our safety evaluations of inVag treatment revealed that adverse events were unrelated to the use of the preparation or were reported as unlikely to be related and having mild severity.”
Mastromarino, P., Macchia, S., Meggiorini, L., Trinchieri, V., Mosca, L., Perluigi, M., & Midulla, C. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02112.x · Cited by 194
Cited by
The role of lactic acid production by probiotic Lactobacillus species in vaginal health
Tachedjian, G., Aldunate, M., Bradshaw, C. S., & Cone, R. A. (2017) · Research in Microbiology · doi:10.1016/j.resmic.2017.04.001 · Cited by 557
van de Wijgert, J., & Verwijs, M. (2020) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.15870 · Cited by 162
López-Moreno, A., & Aguilera, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071461 · Cited by 97
Bacterial vaginosis: A state of microbial dysbiosis
Mondal, A. S., Sharma, R., & Trivedi, N. (2023) · Medicine in Microecology · doi:10.1016/j.medmic.2023.100082 · Cited by 44
Blancafort, C., & Llácer, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1081830 · Cited by 23
Metadata
- Authors
- Tomusiak, A., Strus, M., Heczko, P., Adamski, P., Stefański, G., Mikołajczyk-Cichońska, A., & Suda-Szczurek, M.
- Venue
- Drug Design, Development and Therapy
- Publisher
- Informa UK Limited
- Published
- 2015-09
- Volume
- 9
- Pages
- 5345
- ISSN
- 1177-8881 (ISSN-L)
- OpenAlex
- W1938621374
- Cited by
- 54
- References
- 2
- FWCI
- 1.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.